Efficacy and safety study of osimertinib in advanced non-small cell lung cancer (NSCLC) with EGFR mutation

被引：0
|
作者：
Garcia Samblas, Victoria [1 ]
Fernandez Madrigal, Laura [1 ]
Rodriguez Garces, Maria Yeray [1 ]
Inoriza, Angel [1 ]
机构：
[1] Hosp Juan Ramon Jimenez, Huelva, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21150
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Osimertinib and pterostilbene in EGFR-mutation-positive non-small cell lung cancer (NSCLC)
    Paulina Bracht, Jillian Wilhelmina
    Karachaliou, Niki
    Berenguer, Jordi
    Pedraz-Valdunciel, Carlos
    Filipska, Martyna
    Codony-Servat, Carles
    Codony-Servat, Jordi
    Rosell, Rafael
    [J]. INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2019, 15 (12): : 2607 - 2614
  • [2] Efficacy and Safety of Osimertinib in a Hemodialysis Patient With Advanced Non-Small Cell Lung Cancer
    Iwafuchi, Yoichi
    Saito, Isao
    Narita, Ichiei
    [J]. THERAPEUTIC APHERESIS AND DIALYSIS, 2017, 21 (04) : 416 - 417
  • [3] Osimertinib rechallenge in advanced EGFR non-small cell lung cancer patients
    Uy, Natalie F.
    Tratt, Micah
    Eaton, Keith D.
    Santana-Davila, Rafael
    Baik, Christina S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [4] Safety of osimertinib in EGFR-mutated non-small cell lung cancer
    Mezquita, Laura
    Varga, Andreea
    Planchard, David
    [J]. EXPERT OPINION ON DRUG SAFETY, 2018, 17 (12) : 1239 - 1248
  • [5] INDIRECT COMPARISON OF EFFICACY AND SAFETY FOR AUMOLERTINIB VS OSIMERTINIB IN PATIENTS WITH EGFR-MUTANT NON-SMALL CELL LUNG CANCER (NSCLC)
    Stergiopoulos, S.
    King, S.
    Curtis, M.
    Dillon, S. A.
    Akehurst, R.
    Lee, D.
    Guelfucci, F.
    Ngami, A.
    Bianic, F.
    Li, Y.
    Ma, X.
    Ali, S.
    Miller, V. A.
    Popat, S.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S42 - S42
  • [6] EGFR mutation in non-small cell lung cancer(NSCLC) in South Croatia
    Mladinov, Suzana
    Skopljanac, Ivan
    Ivcevic, Veljka
    Kuret, Sendi
    Durdov, Meri Glavina
    Mise, Kornelija
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [7] EGFR mutation and management of advanced non-small cell lung cancer (NSCLC) adenocarcinoma in Germany and France
    Souquet, P. J.
    Dietel, M.
    Eberhardt, W.
    Fournel, P.
    Von der Schulenburg, J. M. Graf
    Locher, C.
    Sabourin, J. C.
    Schirmacher, P.
    Thomas, M.
    Schuette, W.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S817 - S817
  • [8] Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study
    Schuler, A.
    Huser, J.
    Schmid, S.
    Schar, S.
    Scherz, A.
    Gautschi, O.
    Mauti, L.
    von Briel, T.
    Waibel, C.
    Pankovics, J.
    Mark, M. T.
    Rothschild, S. I.
    Addeo, A.
    Janthur, W. D.
    Siano, M.
    Boos, L.
    Britschgi, C.
    Fruh, M.
    [J]. LUNG CANCER, 2024, 187
  • [9] Targeting β-catenin enhances the therapeutic efficacy of osimertinib in EGFR- mutant non-small cell lung cancer (NSCLC).
    Suman, Shankar
    Guan, Shu-Xiao
    Navari, Nastaran
    Arasada, Rajeswara Rao
    Carbone, David P.
    Memmott, Regan M.
    [J]. CANCER RESEARCH, 2021, 81 (13)
  • [10] Osimertinib beyond Progression in Patients with EGFR Mutated Non-small Cell Lung Cancer (NSCLC) Receiving Frontline Osimertinib
    Benyounes, A.
    Cohen, A.
    Rossi, S. Diamond
    Cannon, T.
    Yacur, M.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S657 - S657
12345